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The volume of the HR-CTV not covered with the prescribed 
isodose was 19.8 ccm. Oblique needles applied at the time of 
the second application contributed significantly to a better 
dose coverage of HR-CTV (D90=109%, D100=55%, V100=93%). 
The part of the volume not sufficiently covered with the 
prescribed dose in the first application was boosted using 
only oblique needles at the end of the second treatment until 
the dose restrictions for the OAR were reached (Figure 1b). 
DVH parameters for HR-CTV of the second application were 
improved accordingly: D90=119%, D100=61%, V100=96%. The 
volume of the HR-CTV not covered with the prescribed 
isodose was reduced to 2.4 ccm. The position on the ring, 
oblique angle and the insertion depth of the oblique needles 
in the second application were measured on the MR images 
and compared with the pre-plan. The average differences 
were relatively small (position on the ring: 10°, oblique 
angle: 8°, insertion depth: 4 mm). 
 
Conclusion: Individualized approach to cervical cancer 
patients with extensive parametrial involvement at the time 
of brachytherapy can contribute significantly to an improved 
dose coverage of the HR-CTV. An individualized 3D printed 
interstitial cap for the ring applicator with oblique needles is 
an efficient option for these patients. 
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Purpose or Objective: The aim is to report the results 
obtained in patients diagnosed of endometrial carcinoma 
stage IA-IIA treated with surgery followed by adyuvant 
brachytherapy at our institution. 
 
Material and Methods: From 2006 until 2013, 116 patients 
with endometrial carcinoma stage IA-IIA have been treated 
with surgery and exclusive vaginal brachytherapy. Median age 
of the series was 62 years. Total hysterectomy, double 
anexectomy, pelvic lymphadenectomy and peritoneal 
washing was made in 61,4 %. The majority of the 
pathologycal FIGO stages were IB (77,2 %). Exclusive 
brachytherapy was performed using vaginal cylinders with 3 
cm of diameter (50,9 %). The reference isodosis covering the 
proximal 3 cm of the vagina (96,4 %). The dose was specified 
at 5 mm distant from the surface of the cylinder. Dose 
schedule with high dose rate brachytherapy was 21 Gy in 3 
fractions. The median of dose equivalent received in the 
rectum was 31,8 Gy and in bladder 38 Gy. 
 
Results: At the moment of this analysis there are 4 relapses: 
2 of them live with disease, and 2 death for tumor; 110 cases 
live without disease (94,82 %), and 2 cases death for another 
cause. With median follow-up of 26 months, free disease 
survival was 90.2% and 2 years overall survival was 88.3%. No 
toxicity was reported in the 52,6%, and when it was present 
the most frequent was cystitis (12.3%).  
 
Conclusion: The exclusive vaginal brachytherapy is effective 
in ensuring vaginal control, with few toxic effects. So, this 
schedule should be an adyuvant treatment for these patients. 
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Purpose or Objective: The purpose of this study is to analyze 
the efficacy and complication rates of postoperative high 
dose rate (HDR) vaginal brachytherapy(VBT) to determine 
whether VBT with lower dose per fraction(3-4 Gy/fraction) is 
as effective as pelvic external beam radiotherapy (EBRT) for 
patients with stage 1 endometrial carcinoma 
 
Material and Methods: From March 2000 to April 2014, 43 
patients with FIGO stage I endometrial cancer underwent 
adjuvant radiotherapy following surgery. Twenty five 
patients received postoperative HDR VBT alone, while 18 
patients received postoperative EBRT to the whole pelvis. 
Among these patients, three patients were treated with EBRT 
plus VBT. The median treatment dose of EBRT was 50.0 Gy 
(45.0-50.4 Gy) and HDR VBT dose was five to six fractions of 3 
or 4 Gy to a total dose of 15-24 Gy. The tumor dose was 
prescribed at a depth of 5mm from the cylinder surface and 
delivered twice per week. 
 
Results: The median follow up period of all patients was 54.4 
(range 9-142) months. Five year disease free survivals (DFS) 
and overall survivals (OS) for all patients were 91.5% and 
91.2%, respectively. Five year DFS of EBRT and brachytherapy 
was 87.2% and 96.0%, respectively (p=0.46), and five year OS 
of EBRT and brachytherapy was 86.9% and 95.7%, respectively 
(p=0.43). There were no differences in 5 year DFS or OS 
according to radiation treatment group. There were no 
locoregional recurrences for all patients. Two patients who 
received EBRT and one patient who received brachytherapy 
alone developed distant metastatic disease. There were one 
patient who had grade 3 gastrointestinal complication and 
one patient who had pelvic bone insufficiency fracture. Two 
patients who had severe complication were treated with 
EBRT. 
 
Conclusion: HDR VBT with lower dose per fraction alone 
showed high DFS and OS with no severe adverse effect. HDR 
VBT with small fraction size may be adequate for early stage 
endometrial cancer following surgery. 
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Purpose or Objective: Controversies still exist in the method 
of treatment planning and applicator reconstruction in 
adaptive cervix brachytherapy. This study aims to compare 
any difference between MRI and CT applicator reconstruction 
and the treatment planning process at our institution. 
 
Material and Methods: Our analysis included 15 patients 
from our institution with stage IB2-IVA cervical cancers 
between January to October 2015, all patients treated with 
chemoradiation and brachytherapy. We followed the Vienna 
schedule for HDR brachytherapy at week 6 and 7, with 2 
weekly insertions with 2 consecutive fractions per week. MRI- 
and CT- based treatment planning and applicator 
reconstruction were done for every patient. Contours and 
dosimetry of tumor target (HRCTV D90) and organs at risk (D2cc 
bladder, rectum, sigmoid and small bowel) were compared. 
Applicator reconstruction techniques, possible challenges and 
errors between the 2 imaging modalities were analysed. 
 
Results: Both CT- and MR- based applicator reconstruction 
uncertainties were less than 1 mm for either tandem-and-
ovoids (T&O) or tandem-and-ring (T&R) applicators. 
Compared with T&O applicators, use of rigid T&R applicators 
gave more accurate applicator reconstruction. When an 
applicator library was used, the T&O reconstruction 
uncertainties always occurred in posterior-anterior direction 
while T&R reconstruction uncertainties were found when it 
rotated. Applicator holes for interstitial needles could 
provide additional markers to define correct applicator 
rotation on MRI. The D2cc rectum value was the most sensitive 
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to the T&O reconstruction. Without availability of MRI 
markers for needle visualization, manual MR-based needle 
reconstruction could be challenging especially in tissues of 
similar signal intensities. Measurement of remaining 
interstitial needle length outside patient could open up a 
potential solution path. 
 
Conclusion: Despite minor distortions around centre of the 
magnet, MRI distortions do not play a major role in applicator 
reconstruction uncertainties. Both CT- and MR-based 
applicator reconstruction are feasible when used with 
applicator library, providing accurate source pathway 
reconstruction. Applicator holes for interstitial needles and 
physical measurement of needle outside patient could 
provide valuable information to improve the reconstruction 
accuracy. 
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Purpose or Objective: The aim of this work is to evaluate 
outcomes after adjuvant brachytherapy of the lip cancer 
after surgical resection with close (<5mm) or positive 
margins. 
 
Material and Methods: A total of 20 patients (3 women and 
17 men in median age of 65,5) diagnosed between 2010 ad 
2014 with clinical T1 – T2 N0 lip carcinoma were treated 
primarly by surgical tumor resection with or without 
lymphadenectomy. After histopathological result (40% 
positive, 60% close margins) they were qualified for adjuvant 
brachytherapy. At the discretion of the attending physician 
25% of patients were treated by high dose rate (HDR) and 75% 
by pulse dose rate (PDR) brachytherapy. The mean 
biologically effective dose (BED) given to the clinical target 
volume were 71,285 Gy (range 62,6 – 75 Gy). The mean 
follow up (counted from the end of BT course to the last 
control visit or recurrence) were 24 months. For statistical 
calculations we used the Kaplan-Meier method and the U 
Mann-Whitney test. 
 
Results: Sole patient in the group had nodal reccurence 6 
months after treatment. The rest of the patients had no 
evidence of recurrence during the follow up. Estimated 4-
year disease-free survival rate was 95%. The acute skin 
toxicity according to RTOG scale was 65%, 30% and 5% for 
grade I, II, and III respectively; the late skin toxicity was 25%, 
5% and 5% for grade I, II, and IV respecively. We also found a 
statistically significant correlation between the higher BED 
and appearance of acute toxicity greater than I grade 
(p=0,014) and occurrence of any late toxicity (p=0,047). 
 
Conclusion: Adjuvant brachytherapy in the treatment of the 
T1-T2 lip tumors achieves a long loco-regional control with 
relatively low toxicity and it may be taken into consideration 
for the adjuvant therapy of the lip cancer after surgical 
resection with close (<5mm) or positive margins. Such 
regimen allows to prevent reoperations along with large 
reconstructive surgery. 
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Purpose or Objective: Patients with head and neck cancers 
can develop recurrences in previously treated areas, which 
usually involve the neighbor carotid artery. In the majority of 
these patients a complete surgical resection is not possible, 
R1/R2 resections are frequent. We proved the feasibility and 
long-term outcome of perioperative intensity modulated 
brachytherapy (IMBT) as a salvage treatment option for 
advanced neck metastases in combination of carotid artery 
preservation. 
 
Material and Methods: From 2006 to 2014, nine patients at 
the University Hospital of Schleswig-Holstein Campus Luebeck 
had received an interdisciplinary salvage treatment with 
debulking surgery and perioperative HDR-IMBT for advanced 
recurrent neck metastases. Median age was 53 years, range: 
38- 66, the mean follow-up was 66 months. Surgery was 
performed with primary wound closure in seven patients, 
while myocutaneus flap was used in two patients. Active 
phase of IMBT started 4-12 days following surgery. The 
prescription dose was 2.5Gy twice daily (average total dose: 
27Gy, range: 15-30Gy). Dose non-homogeneity ratio (DNR) 
never exceeded 0.42. We used the manual dose-volume 
optimization method and planned biologicaly correct 
hot/cold spot areas within the dose distribution. The 
reference isodose was defined within a maximum of 10 mm 
lateral distance from the interstitial tube and the Dmax was 
defined in 400% on the catheter surface. 
 
Results: For initial treatments, all patients received previous 
surgery; eight patients received also external beam radiation 
with an average dose of 64Gy. Two and five year overall 
survival estimates were 78% and 67% respectively. The 
median survival rate was 65 months. Only two patients had a 
second neck recurrence after 62 and 65 months. Early 
toxicities (grade I-II) recorded in four patients and were 
limited to local edema and skin infection, no treatment 
related grade 3 or 4 toxicities recorded. 
 
Conclusion: Salvage debulking surgery combined with 
perioperative HDR-IMBT seems to be feasible and safe 
treatment option for selected recurrent neck metastases with 
minimal treatment related toxicities. 
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Purpose or Objective: To assess the feasibility, safety and 
clinical outcome of MRI based and ultrasound guided high-
dose-rate interstitial brachytherapy technical in isolated 
lymph node metastases from different solid cancers. 
 
Material and Methods: From January 2013 to May 2014, 11 
patients (six males and four females) with isolated nodal 
metastases were treated with MRI based and ultrasound 
guided high-dose-rate brachytherapy. All patients had 
previously been treated with radical radiotherapy or 
chemoradiation with or without surgery. Seven lymph node 
metastases were cervical, three metastases were at the 
supraclaviculares, one metastasis located at a left inguinal 
nodal. Pathologically, six metastases were squamous 
carcinoma, three were small cell cancer and two were adeno 
carcinoma. The mean lesion diameter was 38.5 mm (range 
21.0- 78.0 mm). The brachytherapy were achieved by 
inserting the titanium needle to the target, avoiding vascular 
and organ injury under the ultrasound guidance, following by 
MRI scanning and delineating the targets. The metastases 
were treated by single-fraction irradiation using the 
afterloading technique using an Iridium-192 radiation source. 
The prescribed salvage dose of brachytherapy was 5 
